Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter
CONCLUSION: In addition to fracture prevention, anti-osteoporotic treatments for patients with vertebral fractures were associated with a reduction in mortality. A longer duration of treatment and the use of long-acting drugs was also associated with lower mortality.PMID:37120337 | DOI:10.1016/j.jfma.2023.04.004 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - April 29, 2023 Category: General Medicine Authors: Ta-Wei Tai Yi-Lun Tsai Chien-An Shih Chia-Chun Li Yin-Fan Chang Chun-Feng Huang Tien-Tsai Cheng Jawl-Shan Hwang Tsung-Hsueh Lu Chih-Hsing Wu Source Type: research
The Clinical Effectiveness of Denosumab (Prolia ®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis
AbstractTo assess the effectiveness and safety of denosumab (Prolia ®) compared to bisphosphonates (alendronate, ibandronate, risedronate, zoledronate), selective estrogen receptor modulators (SERMs; bazedoxifene, raloxifene) or placebo, for the treatment of osteoporosis in postmenopausal women (PMW). Systematic searches were run in PubMed, Embase& Cochrane Library on 27-April-2022. Randomized controlled trials (RCTs) that included osteoporotic PMW allocated to denosumab, SERMs, bisphosphonates, or placebo were eligible for inclusion. RCTs were appraised using Cochrane Risk of Bias 2.0. Bayesian network and/or pairwis...
Source: Calcified Tissue International - April 5, 2023 Category: Orthopaedics Source Type: research
The impacts of menopausal hormone therapy on longer-term health consequences of ovarian hormone deficiency
This study on the longer-term health consequences of ovarian hormone deficiency (OHD) received the Henry Burger Prize in 2022. Osteoporosis, cardiovascular disease and dementia are major degenerative diseases that are also causally associated with OHD. Two randomized controlled trials (RCTs) revealed no significant difference in bone mineral density by adding alendronate to ongoing menopausal hormone therapy (MHT) or combining alendronate at MHT initiation. Another RCT pursuing the effects on fracture recurrence and total mortality in women with hip fracture disclosed that MHT with percutaneous estradiol gel (PEG) and micr...
Source: Climacteric - April 3, 2023 Category: Geriatrics Authors: B-K Yoon Source Type: research
The impacts of menopausal hormone therapy on longer-term health consequences of ovarian hormone deficiency
This study on the longer-term health consequences of ovarian hormone deficiency (OHD) received the Henry Burger Prize in 2022. Osteoporosis, cardiovascular disease and dementia are major degenerative diseases that are also causally associated with OHD. Two randomized controlled trials (RCTs) revealed no significant difference in bone mineral density by adding alendronate to ongoing menopausal hormone therapy (MHT) or combining alendronate at MHT initiation. Another RCT pursuing the effects on fracture recurrence and total mortality in women with hip fracture disclosed that MHT with percutaneous estradiol gel (PEG) and micr...
Source: Climacteric - April 3, 2023 Category: Geriatrics Authors: B-K Yoon Source Type: research
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools
ConclusionAn offer of 2-step screening with risk assessment and BMD measurement toselected postmenopausal females with low prevalence of prior fracture probably results in a small reduction in the risk of clinical fragility fracture and hip fracture compared to no screening. These findings were most applicable to the use of clinical FRAX for risk assessment and were not replicated in theoffer-to-screen population where the rate of response to mailed screening questionnaires was low. Limited direct evidence on harms of screening were available; using study data to provide estimates, there may be a moderate degree of overdia...
Source: Systematic Reviews - March 21, 2023 Category: International Medicine & Public Health Source Type: research
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA
ConclusionsDiscontinuation rates of oral bisphosphonate therapy were high. However, women initiated on GR risedronate had a significantly lower risk of fracture for several skeletal sites than women initiated on IR risedronate/alendronate, particularly those aged ≥ 70 years. (Source: Osteoporosis International)
Source: Osteoporosis International - March 6, 2023 Category: Orthopaedics Source Type: research
Denosumab prevented periprosthetic bone resorption better than risedronate after total hip arthroplasty
ConclusionDenosumab is more effective in preventing periprosthetic bone resorption than risedronate in the proximal femur. It also increased BMD around the stem implant following THA. (Source: Journal of Bone and Mineral Metabolism)
Source: Journal of Bone and Mineral Metabolism - February 6, 2023 Category: Orthopaedics Source Type: research
Effects of a locally administered risedronate/autogenous bone graft combination on bone healing in a critical-size rabbit defect model
Risedronate is a bisphosphonate with poor oral absorption. An extremely hydrophilic molecule that has a high affinity for bone, risedronate also inhibits the farnesyl diphosphate synthase enzyme, inhibiting os... (Source: Journal of Orthopaedic Surgery and Research)
Source: Journal of Orthopaedic Surgery and Research - February 4, 2023 Category: Orthopaedics Authors: Taha Özer, Vusala Guliyeva, Alper Aktaş, Emre Barış and Mert Ocak Tags: Research article Source Type: research
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study
ConclusionPersistence was highest for denosumab followed by alendronate. We identified several factors associated with treatment persistence, some of which were the same irrespective of OTx agent, which could help target subgroups of patients in terms of social and healthcare support. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - January 11, 2023 Category: Orthopaedics Source Type: research
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study
ConclusionPersistence was highest for denosumab followed by alendronate. We identified several factors associated with treatment persistence, some of which were the same irrespective of OTx agent, which could help target subgroups of patients in terms of social and healthcare support. (Source: Archives of Osteoporosis)
Source: Archives of Osteoporosis - January 11, 2023 Category: Orthopaedics Source Type: research
Bisphosphonates for osteoporosis in people with cystic fibrosis
CONCLUSIONS: Oral and intravenous bisphosphonates may increase bone mineral density in people with cystic fibrosis, but there are insufficient data to determine whether treatment reduces fractures. Severe bone pain and flu-like symptoms may occur with intravenous bisphosphonates. Before any firm conclusions can be drawn, trials in larger populations, including children, and of longer duration are needed to determine effects on fracture rate and survival. Additional trials are needed to determine if bone pain is more common or severe (or both) with the more potent zoledronate and if corticosteroids can ameliorate or prevent...
Source: Cochrane Database of Systematic Reviews - January 10, 2023 Category: General Medicine Authors: Tomas C Jeffery Anne B Chang Louise S Conwell Source Type: research
Bisphosphonates for osteoporosis in people with cystic fibrosis
CONCLUSIONS: Oral and intravenous bisphosphonates may increase bone mineral density in people with cystic fibrosis, but there are insufficient data to determine whether treatment reduces fractures. Severe bone pain and flu-like symptoms may occur with intravenous bisphosphonates. Before any firm conclusions can be drawn, trials in larger populations, including children, and of longer duration are needed to determine effects on fracture rate and survival. Additional trials are needed to determine if bone pain is more common or severe (or both) with the more potent zoledronate and if corticosteroids can ameliorate or prevent...
Source: Cochrane Database of Systematic Reviews - January 10, 2023 Category: General Medicine Authors: Tomas C Jeffery Anne B Chang Louise S Conwell Source Type: research
The clinical effectiveness of denosumab (Prolia ®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
ConclusionIn MPC on HAT, denosumab (relative to placebo) was effective at preventing vertebral fractures and improving BMD at the FN and LS. Moreover, in WBC on AAIT, denosumab (relative to placebo) improved BMD at the FN, LS, TH, and TRO, as well as prevent vertebral fracture. (Source: Archives of Orthopaedic and Trauma Surgery)
Source: Archives of Orthopaedic and Trauma Surgery - January 10, 2023 Category: Orthopaedics Source Type: research
